共 2 条
[2]
Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: Induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity[J] . C. Scheid,R. Young,R. McDermott,L. Fitzsimmons,J. H. Scarffe,P. L. Stern.Cancer Immunology Immunotherapy . 1994 (2)